HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nutrition Giant DSM Unveils New Indian Site To Gain Local Edge

This article was originally published in PharmAsia News

Executive Summary

Dutch conglomerate DSM has established a brand new dietary supplements manufacturing site in India. The company forecasts strong growth in the segment, and the new unit, which will replace imports, is preparing for quicker lead times and localized solutions.

You may also be interested in...



DSM Forms 50-50 Joint Venture With Sinochem To Crack Into China's Restricted Anti-Infectives Market

SHANGHAI - Netherlands-based Royal DSM announced Dec. 17 that it reached an agreement with Sinochem Group, one of China's biggest central state-owned enterprises, to form a global 50-50 joint venture for anti-infectives. The two companies expect to close the transaction in Q2 2011

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Lee Takes India Compulsory License Fight To Saxagliptin

In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel